P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2

J. Chouitar; S. Vincent; R. Brake; S. Li

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2

【24h】

P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2

机译：P2.13-32 TAK-788是一种新颖和有效的酪氨酸激酶抑制剂，具有针对EGFR / HER2的选择性活动

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
J. Chouitar; S. Vincent; R. Brake; S. Li;
展开▼
作者单位

Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;

Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;

Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;

Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2 [J] . J. Chouitar, S. Vincent, R. Brake, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P2.13-32 TAK-788是一种新颖和有效的酪氨酸激酶抑制剂，具有针对EGFR / HER2的选择性活动
2. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. [J] . Wang SE, Narasanna A, Perez Torres M, Cancer Cell . 2006,第1期

机译：HER2激酶结构域突变导致HER2和EGFR的组成型磷酸化和激活以及对EGFR酪氨酸激酶抑制剂的耐药性。
3. Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases? [J] . Thomas Beckers, Siavosh Mahboobi, Andreas Sellmer, MedChemComm . 2012,第7期

机译：嵌合设计的HDAC和酪氨酸激酶抑制剂。一系列厄洛替尼杂种作为EGFR，HER2和组蛋白脱乙酰基酶的双重选择性抑制剂？
4. Taking Quinazoline as a General Support-Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS-like Tyrosine Kinase 3 [C] . Wei-Wei Li, Luo-Ding Yu, Li-Juan Chen, ICMSI;International conference of molecular simulations and applied informatics technologies . 2010

机译：以喹唑啉作为一般支持物来设计有效和选择性激酶抑制剂：在类似FMS的酪氨酸激酶3中的应用
5. Pharmacological Characterization of TAS05567, a Potent and Selective Inhibitor of Spleen Tyrosine Kinase, in Animal Models of Inflammatory Diseases and B-cell Malignancies [D] . 林宏明 2019

机译：TAS05567，脾酪氨酸激酶的强效和选择性抑制剂，在炎症性疾病和B细胞恶性动物模型中的药理特性
6. Lapatinib a Dual EGFR and HER2 Tyrosine Kinase Inhibitor Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2 [O] . Hwang-Phill Kim, Young-Kwang Yoon, Jin-Won Kim, 2009

机译：拉帕替尼一种EGFR和HER2酪氨酸激酶双重抑制剂通过抑制EGFR和HER2的核转运而下调胸苷酸合酶。
7. Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors [O] . Lorenza Landi, Marcello Tiseo, Rita Chiari, 2014

机译：EGFR-HER2双重抑制剂AFATINIB在EGFR-突变体肺癌患者中获得可逆EGFR酪氨酸激酶抑制剂的抗性

P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2

著录项

相似文献

相关主题

期刊订阅